SUPPORTING global supply demand, Sanofi will help Moderna manufacture up to 200m doses of the biotechnology company’s Covid-19 vaccine in the US, starting in September.
An agreement between the companies will see Sanofi use its established infrastructure and manufacturing expertise at a site in Ridgefield, New Jersey, US, to fill-and-finish Moderna’s vaccine.
This marks Sanofi’s third commitment to provide manufacturing support. According to the biopharmaceutical company, it is the only company lending manufacturing capacity and expertise to support three different types of Covid-19 vaccines.
Sanofi’s previous agreements were with BioNTech and Johnson and Johnson. In January, Sanofi announced it would support BioNTech in producing 125m vaccine doses for the EU. A month later, Sanofi revealed that its manufacturing site in France would be used to aid production of 12m doses/month of Covid-19 vaccines for Johnson and Johnson.
Paul Hudson, CEO of Sanofi, said: “Since the beginning of the pandemic, we have been mobilising on multiple fronts and we showed solidarity across the industry.
“We are one of the few pharmaceutical companies to leverage many industrial partnerships to improve global supply and access to Covid-19 vaccines, while in parallel, also continuing to develop our two Covid-19 vaccine programmes.”
Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.